The eight-member expert committee, which is in charge of revising NLEM, plans inclusion of new drugs to the list and also do away with the current practice of including only specific strengths of medicines in NLEM.
Godrej Agrovet Ltd, the agri-business arm of leading conglomerate Godrej Ltd, plans to enter the dairy farming business. The company is in talks with at least two leading Israeli dairy farm technology providers.
The first-ever study conducted by the National Pharmaceutical Pricing Authority (NPPA) on cancer medicines has found huge price variations among different brands of same medicines sold in the country.
The structure and the exact mandate of the high-level committee set up to probe the alleged financial irregularities related to the conduct of the Commonwealth Games 2010 remain unclear even a week after the setting up of the panel was announced.
Beleaguered drugmaker Wockhardt has a new management team in place to implement a three-year strategic plan to get back on track. The company has seen at least four senior-level exits in the last few months.
The studies, independently initiated by international non-governmental-organization PATH and Indian Council of Medical Research for GSK and Merck vaccines respectively, were called off early this year after six deaths were reported among the girls who were administered these vaccines in Gujarat and Andhra Pradesh.
Several international insurance firms that operate in India through joint ventures exercise control over them, despite having only a 26 per cent stake. This is the maximum permissible foreign investment.
The Reliance-Anil Dhirubhai Ambani Group has picked up a 15 per cent stake for Rs 225 crore (Rs 2.25 billion) in a new international airport coming up at Aranmula in Pathanamthitta district of central Kerala.
Says sector has grievance redress mechanism.
The National Pharmaceutical Pricing Authority, which regulates the prices of medicines, has identified around 70 anti-cancer drugs, including anti-breast cancer medication Letrozole and anti-blood cancer drug Imatinib, for detailed price analysis.
Major Indian drug companies such as Ranbaxy Laboratories, Lupin, Dr Reddy's Laboratories and Glenmark have gone off the beaten track in overseas markets.
The Prime Minister's Office (PMO) has sought the opinion of various stakeholder departments on the need for further amendments to the patent law to introduce some of the controversial provisions that were kept out during the previous amendment to the Indian Patent Act five years ago.
The Planning Commission has decided that approvals for all social sector projects undertaken by various non-government organisations, normally outside the purview of CAG, will come with the rider that they will be subject to audit, if required.
The Union ministry of chemicals and fertilisers has initiated a move to bring all essential medicines sold in the country under a price cap.
The Competition Commission of India, the country's fair trade watchdog, which turned functional less than a year ago, busy these days.
Major drug discovery outsourcing deals have almost dried up in the past 18 months for almost all prominent players in the area
Piramal Healthcare is planning a string of acquisitions in the biotech space in the US, Europe and Canada in the next two to three years.
Pune-based Serum Institute of India will soon become the second company to get manufacturing approval for a vaccine for the H1N1 virus (swine flu) . The company's intra-nasal swine flu vaccine is expected to get regulatory clearance by the month-end, health ministry officials said.
An increase in the number of outsourcing deals between domestic drug companies and pharmaceutical multinationals has triggered huge capacity expansion programmes in the drug manufacturing sector.
Fortis Healthcare may avoid a hurried response to counter Malaysian investment fund Khazanah's bid to acquire management control over Asia's largest health care chain Parkway Holdings from Fortis which holds the largest number of shares in Parkway.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances